PleoPharma

Great to be part of the conversations happening at BIO International Convention this week around innovation in biotech and the future of patient care. For PleoPharma, moments like this are an opportunity to discuss the urgent unmet need in cannabis use disorder and the importance of advancing science in addiction medicine. We're proud to share recent progress, including data on cannabis withdrawal in adults with cannabis use disorder, as well as continued advancement of PP-01, our investigational product currently being evaluated in a Phase 3 clinical trial. We appreciate the chance to connect with peers, partners, and investors who are focused on improving outcomes for patients. #BIO2026 

PleoPharma is featured in a new BioSpectrum Asia piece, out today ahead of our presentation at BIO International Convention.    In the article, our Chief Business Officer Jason Goodson, walks through our Phase 3 program, our FDA Fast Track designation, and why mitigating cannabis withdrawal symptoms, not just cravings, is central to improving long-term outcomes for the millions of people living with cannabis use disorder.    Read the full piece: https://lnkd.in/grY6jVek

We're proud to announce an important milestone for PleoPharma: the first patient has been dosed in our Phase 3 CAN-004 clinical trial evaluating PP-01 for the mitigation of cannabis withdrawal symptoms in adults with cannabis use disorder.   With no FDA-approved treatments currently available to specifically address cannabis withdrawal symptoms, this study represents an important step toward advancing a potential new treatment option for people living with cannabis use disorder. Read the full announcement:  https://lnkd.in/g5ifHsPh

The PleoPharma team is at ASAM, and we're looking forward to connecting with everyone over the coming days. Stop by the PleoPharma booth (no. 700) to see what we've been building and chat with our team. #ASAM

The PleoPharma team is looking forward to meeting everyone in person at Centri in NYC soon! Meet us at 8:30am Track 3 with Jason Goodson to learn more about our PP-01 asset. #Addiction #CannabisUseDisorder #CannabisWithdrawal #FastTrack https://lnkd.in/gwE56aU7

Come see Jason at Biotech Showcase next week speaking for PleoPharma!

We're thrilled to announce the closing of our $36 million Series B financing round! 🎉 This milestone represents more than just capital—it's a vote of confidence in our mission to address a growing public health challenge. With over 20 million Americans living with Cannabis Use Disorder and no FDA-approved treatment options available, the need has never been greater. The proceeds from this round will advance PP-01, our investigational treatment and the first and only Fast Track-designated therapy for cannabis withdrawal in patients with Cannabis Use Disorder, into Phase 3 clinical trials. We're grateful to our investors—both new partners and returning Series A supporters—who share our commitment to developing treatments for those struggling with cannabis addiction and withdrawal. To everyone on the PleoPharma team: this is your achievement. Your dedication to advancing science and helping underserved patients drives everything we do. https://lnkd.in/ePD3EKz6 #ClinicalTrials #Biotech #PublicHealth #AddictionMedicine #Neuropsychiatry #SeriesBFunding